Key facts
- It has raised $10.0M across 1 recorded rounds; the latest was Accelerator/Incubator in Jan 2022.
- Notable investors include Creative Destruction Lab, Springboard Enterprises, University of Toronto, University of Toronto Entrepreneurship, Innovation Factory (Hamilton) — 9 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Paradox Immunotherapeutics
Funding rounds
1 roundsAbout Paradox Immunotherapeutics
Operator of a biotech company intended to develop a front-line monoclonal antibody treatment for protein misfolding diseases. The company provides the identification and development of specialized antibodies that can selectively target only the problematic misfolded proteins while leaving the healthy proteins in the body untouched, enabling healthcare providers to empower their immune system with the tools to combat protein misfolding diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2019
- Employees
- 9
- Website
- paradoximmuno.com/
- Ownership
- Privately Held (backing)
Paradox Immunotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Paradox Immunotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Paradox Immunotherapeutics in its N-PORT filings yet. We sweep new filings monthly.